AGILIS BIOTHERAPEUTICS
Agilis Biotherapeutics develops DNA therapeutics for patients with rare diseases of the central nervous system (CNS) that single-gene defects cause. Its technology enables precise targeting and restoration of lost gene function while avoiding unintended off-target effects. Agilis Biotherapeutics also provides DNA therapeutics for patients with AADC Deficiency, a rare CNS disorder arising from reductions in the enzyme aromatic L-amino acid decarboxylase (AADC) that causes the inability to devel... op any motor strength and control resulting in breathing, feeding, and swallowing problems. Moreover, it offers DNA therapeutics for Friedreich’s Ataxia, a rare and life-shortening neurodegenerative disease caused by a single defect in the FXN gene, which causes reduced production of the frataxin protein, and DNA therapeutics for Angelman Syndrome (AS), a rare genetic, neurological disorder characterized by severe developmental delays. Agilis Biotherapeutics has a strategic partnership with Intrexon Corporation. It began its operation in 2013, with its headquarters in Lynnfield, Massachusetts.
AGILIS BIOTHERAPEUTICS
Industry:
Biotechnology Health Care Personal Health Pharmaceutical Therapeutics
Founded:
2013-01-01
Address:
Lynnfield, Massachusetts, United States
Country:
United States
Website Url:
http://www.agilisbio.com
Total Employee:
11+
Status:
Active
Contact:
214-706-4340
Email Addresses:
[email protected]
Total Funding:
20.7 M USD
Technology used in webpage:
SPF Domain Not Resolving Apache Microsoft Exchange Online Office 365 Mail Google Maps Sectigo SSL Sectigo Domain SSL Unified Layer AppRiver
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Modis Therapeutics
Modis Therapeutics is bringing disease-modifying therapies to patients with rare genetic diseases.
Current Advisors List
Founder
Investors List
Sands Capital Ventures
Sands Capital Ventures investment in Venture Round - Agilis Biotherapeutics
Official Site Inspections
http://www.agilisbio.com
- Host name: 198-57-149-32.unifiedlayer.com
- IP address: 198.57.149.32
- Location: Provo United States
- Latitude: 40.2342
- Longitude: -111.6442
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84606
